Form 4: SI-BONE Director Sells 4,100 Shares Under 10b5-1 Plan

SI-BONE, Inc. Director Mika Nishimura reported the sale of 4,100 shares of common stock at a weighted average price of $13.8293 per share, executed under a Rule 10b5-1 plan.

Summary

• Mika Nishimura, a Director of SI-BONE, Inc. (SIBN), sold 4,100 shares of the company's common stock.
• The transaction occurred on March 12, 2026, at a weighted average sale price of $13.8293 per share.
• The shares were sold in multiple trades at prices ranging from $13.82 USD to $13.86 USD.
• This transaction was executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Mika Nishimura beneficially owns 32,716 shares of SI-BONE, Inc. common stock.
• The remaining ownership includes 8,675 shares issuable upon the settlement of restricted stock units granted to the Reporting Person.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative signal. While it's an insider sale, the execution under a Rule 10b5-1 plan suggests it was pre-scheduled for personal financial planning rather than a reaction to new, adverse company information, thus mitigating a strong negative interpretation.

Negatives

• A director, Mika Nishimura, reduced their stake in the company by selling 4,100 shares of common stock.
• While executed under a Rule 10b5-1 plan, insider selling can sometimes be interpreted by the market as a signal that the insider believes the stock is fully valued or that future upside may be limited.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even when executed under a Rule 10b5-1 plan, can sometimes be viewed with caution by the market. This transaction by a director of SI-BONE, a medical device company, occurs within an industry where insider activity is common due to compensation structures and personal financial planning. The pre-scheduled nature of the sale mitigates the immediate negative signal compared to an unscheduled transaction.

Comparison to Industry Standards

• StockSavvy.ai observes that insider selling is a common occurrence across all industries, including the medical device sector. While the sale of 4,100 shares by a director is not an exceptionally large volume, it is a notable transaction for an individual insider.
• For context, similar insider sales have been observed in companies like NuVasive (NUVA) or Globus Medical (GMED) where executives periodically sell shares for liquidity or portfolio rebalancing, often under 10b5-1 plans, without necessarily indicating a fundamental shift in company prospects. The key is often the magnitude and frequency of such sales across multiple insiders.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slightly bearish signal, potentially leading to negative sentiment or minor downward pressure on the stock price, despite the 10b5-1 plan.
• Employees are not directly impacted by this transaction, but general market sentiment can indirectly affect the perceived value of their stock-based compensation.

Key Dates

Recommendation

The director's sale of shares, while a reduction in insider holdings, was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled for personal financial planning rather than a reaction to new company developments. This mitigates the typical negative interpretation of insider selling. Investors should hold and monitor for broader company performance and market trends rather than reacting solely to this planned transaction.

Keywords

SI-BONE, SIBN, Insider Sale, Form 4, Director Transaction, Stock Sale, Mika Nishimura, Equity Transaction, 10b5-1 Plan